Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 1/2013

Open Access 01-01-2013 | Original Article

Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease

Authors: Irena Makulska, Maria Szczepańska, Dorota Drożdż, Dorota Polak-Jonkisz, Danuta Zwolińska

Published in: Pediatric Nephrology | Issue 1/2013

Login to get access

Abstract

Background

We examined skin autofluorescence (sAF) in chronic kidney disease children (CKD) in relation to renal function and dialysis modality.

Methods

Twenty children on hemodialysis (HD), 20 on peritoneal dialysis (PD), 36 treated conservatively, and 26 healthy subjects were enrolled into the study. In all children sAF, pulse-wave velocity indexed to height (PWV/ht), left ventricular mass index (LVMI), blood pressure (BP), serum lipid profile, phosphate (P), calcium (Ca), and homocysteine were measured.

Results

sAF was significantly elevated in CKD groups vs. controls and was significantly associated with PWV/ht, LVMI, BP, P, Ca × P product and homocysteine. sAF in HD and PD groups was positively correlated with dialysis vintage, and in the predialysis group negatively correlated with glomerular filtration rate (eGFR). Multiple regression analysis showed significant association of sAF with LVMI and P in the CKD patient group, and with dialysis treatment duration and BP in dialyzed children.

Conclusions

In CKD children, tissue accumulation of advanced glycation end-products (AGEs) was observed. This was aggravated as eGFR declined and was related to early cardiovascular changes and some biochemical cardiovascular disease (CVD) risk markers. sAF as a non-invasive method may be a useful tool for identification of a clinical risk factors of cardiovascular disease in CKD children.
Literature
1.
Groothoff JW, Lilien MR, van de Kar NCAJ, Wolff ED, Davin JC (2005) Cardiovascular disease as a late complication of end-stage renal disease in children. Pediatr Nephrol 20:374–379PubMedCrossRef
2.
Litwin M, Grenda R, Prokurat S, Abuauba M, Latoszyńska J, Jobs K, Boguszewska-Bączkowska A, Wawer ZT (2001) Patient survival and causes of death on hemodialysis and peritoneal dialysis-single center study. Pediatr Nephrol 16:996–1001PubMedCrossRef
3.
Parekh RS, Carrol CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141:191–197PubMedCrossRef
4.
Semba RD, Najjar SS, Sun K, Lakatta EG, Ferrucci L (2009) Serum carboxymethyl-lysine an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens 22:74–79PubMedCrossRef
5.
Suliman ME, Heimburger O, Barany P, Anderstam B, Pecoits-Filho R, Rodríguez Ayala E, Qureshi AR, Fehrman-Ekholm I, Lindholm B, Stenvinkel P (2003) Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patent starting on dialysis therapy. J Am Soc Nephrol 14:1614–1622PubMedCrossRef
6.
Nagano M, Fukami K, Yamagishi S, Sakai K, Kaida Y, Matsumoto T, Hazama T, Tanaka M, Ueda S, Okuda S (2011) Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients. Nephrology 16:299–303PubMedCrossRef
7.
Ueno H, Koyama H, Tanaka S, Fukumoto S, Shinohara K, Shoji T, Emoto M, Tahara H, Kakiya R, Tabata T, Miyata T, Nishizawa Y (2008) Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metab Clin Exp 57:1452–1457PubMedCrossRef
8.
Stein G, Franke S, Mahiout A, Schneider S, Sperschneider H, Borst S, Vienken J (2001) Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant 16:999–1008PubMedCrossRef
9.
McIntyre NJ, Chesterton LJ, John SG, Jefferies HJ, Burton JO, Taal MW, Fluck RJ, McIntyre CW (2010) Tissue-advanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol 5:51–55PubMedCrossRef
10.
Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG (2001) Improved arteria compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104:1464–1470PubMedCrossRef
11.
Ueno H, Koyama H, Fukumoto S, Tanaka S, Shoji T, Shoji T, Emoto M, Tahara H, Inaba M, Kakiya R, Tabata T, Miyata T, Nishizawa Y (2011) Advanced glycation end products, carotid atherosclerosis and circulating endothelial progenitor cells in patients with end-stage renal disease. Metabolism 60:453–459PubMedCrossRef
12.
Rodríguez-Ayala E, Anderstam B, Suliman ME, Seeberger A, Heimbürger O, Lindholm B, Stenvinkel P (2005) Enhanced RAGE-mediated NFkappa-B stimulation in inflamed hemodialysis patients. Atherosclerosis 180:333–340PubMedCrossRef
13.
Herbrig K, Pistrosch F, Oelschlaegel U, Wechmann G, Wagner A, Foerster S, Richter S, Gross P, Passauer J (2004) Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. Am J Kidney Dis 44:840–849PubMed
14.
Smit AJ, Gerrits EG (2010) Skin autofluorescence as a measure of advanced glycation endproduct deposition: a novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens 19:527–533PubMedCrossRef
15.
Hartog JW, Hummel YM, Voors AA, Schalkwijk CG, Miyata T, Huisman RM, Smit AJ, Wan Veldhuisen DJ (2008) Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J Card Fail 14:596–602PubMedCrossRef
16.
Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ (2004) Simple noninvasive assessment of advanced glycation endproduct accumulation. Diabetologia 47:1324–1330PubMedCrossRef
17.
Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ (2006) Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 29:2654–2659PubMedCrossRef
18.
Mulder DJ, van Haelst PL, Gross S, de Leeuw K, Bijzet J, Graaff R, Gans RO, Zijlstra F, Smit AJ (2008) Skin autofluorescence is elevated in patients with stable coronary artery disease and is associated with serum levels of neopterin and the soluble receptor for advanced glycation end products. Atherosclerosis 197:217–223PubMedCrossRef
19.
Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, Smit AJ (2005) Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 16:3687–3693PubMedCrossRef
20.
Meerwaldt R, Lutgers HL, Links TP, Graaff R, Baynes JW, Gans RO, Smit AJ (2007) Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 30:107–112PubMedCrossRef
21.
Hartog JW, Gross S, Oterdoom LH, van Ree RM, de Vries AP, Smit AJ, Schouten JP, Nawroth PP, Gans RO, van Son WJ, Bierhaus A, Bakker SJ (2009) Skin-autofluorescence an independent predictor of graft loss in renal transplant recipients. Transplantation 87:1069–1077PubMedCrossRef
22.
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39:S17–S222CrossRef
23.
Schwartz GJ, Gauthier B (1985) A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 106:522–526PubMedCrossRef
24.
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576CrossRef
25.
Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM (2003) Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 63:1852–1860PubMedCrossRef
26.
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N (1986) Echocardiographic assessment of left ventricular hypertrophy comparison to necropsy findings. Am J Cardiol 57:450–458PubMedCrossRef
27.
de Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH (1995) Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 25:1056–1062PubMedCrossRef
28.
Meerwaldt R, Links T, Graaff R, Thorpe SR, Baynes JW, Hartog J, Gans R, Smit A (2005) Simple noninvasive measurement of skin autofluorescence. Ann NY Acad Sci 1043:290–298PubMedCrossRef
29.
Thornalley PJ, Rabbani N (2009) Highlights and hotspots of protein glycation in end-stage renal disease. Semin Dial 22:400–404PubMedCrossRef
30.
Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW (1999) Alterations in nonenzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications. Kidney Int 55:389–399PubMedCrossRef
31.
Meerwaldt R, Zeebregts CJ, Navis G, Hillebrands JL, Lefrandt JD, Smit AJ (2009) Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am J Kidney Dis 53:138–150PubMedCrossRef
32.
Schmitt CP, von Heyl D, Rieger S, Arbeiter K, Bonzel KE, Fischbach M, Misselwitz J, Pieper AK, Schaefer F (2007) Reduced systemic advanced glycation endproducts in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol Dial Transplant 22:2038–2044PubMedCrossRef
33.
Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H (1991) Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325:836–842PubMedCrossRef
34.
Hasuike Y, Nakanishi T, Otaki Y, Nanami M, Tanimoto T, Taniguchi N, Takamitsu Y (2002) Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reductase in erythrocytes. Am J Kidney Dis 40:464–471PubMedCrossRef
35.
Agalou S, Ahmed N, Babaej-Jadidi R, Dawnay A, Thornalley PJ (2005) Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 16:1471–1485PubMedCrossRef
36.
Tanaka K, Tani Y, Asai J, Nemoto F, Kusano Y, Suzuki H, Hayashi Y, Asahi K, Katoh T, Miyata T, Watanabe T (2011) Skin autofluorescence is associated with renal function and cardiovascular diseases in pre-dialysis chronic kidney disease patients. Nephrol Dial Transplant 26:214–220PubMedCrossRef
37.
Hartog JW, Voors AA, Schalkwijk CG, Scheijen J, Smilde TD, Damman K, Bakker SJ, Smit AJ, van Veldhuisen DJ (2007) Clinical and prognostic value of advanced glycation end-products in chronic heart failure. Eur Heart J 28:2879–2885PubMedCrossRef
38.
Sebeková K, Podracká L, Heidland A, Schinzel R (2001) Enhanced plasma of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation—are they inter-related? Clin Nephrol 56:S21–S26PubMed
39.
Suliman ME, Stenvinkel P, Jogestrand T, Maruyama Y, Oureshi AR, Barany P, Heimburger O, Lindholm B (2006) Plasma pentosidine and total homocysteine levels in relation to change in common carotid intima-media area in the first year of dialysis therapy. Clin Nephrol 66:418–425PubMed
40.
Vishwanath V, Frank KE, Elmets CA, Dauchot PJ, Monnier VM (1986) Glycation of skin collagen in type 1 diabetes mellitus. Correlation with long-term complications. Diabetes 35:916–921PubMedCrossRef
41.
Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ, Khoury PR, Daniels SR (2006) Progression of left ventricular hypertrophy in children with early chronic kidney disease: 2-year follow-up study. J Pediatr 149:671–675PubMedCrossRef
42.
Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS (2004) Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 65:1492–1498PubMedCrossRef
43.
Miyata T, Kurokawa K, Van Ypersele De Strihou C (2000) Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 11:1744–1752PubMed
44.
Tsai C, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME (2005) Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 20:1676–1685
45.
Merouani A, Lambert M, Delvin EE, Genest J Jr, Robitaille P, Rozen R (2001) Plasma homocysteine concentration in children with chronic renal failure. Pediatr Nephrol 16:805–811PubMedCrossRef
46.
Ardissino G (2002) Epidemiology of chronic renal failure. ESPN Handbook. pp 369–372
47.
Hartog JW, Voors AA, Bakker SJ, Smit AJ, van Veldhuisen DJ (2007) Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 9:1146–1155PubMedCrossRef
48.
Smit AJ, Lutgers HL (2004) The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 11:2767–2784PubMedCrossRef
49.
Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB, Collaborative Study Group (2012) Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 11:131–136CrossRef
Metadata
Title
Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease
Authors
Irena Makulska
Maria Szczepańska
Dorota Drożdż
Dorota Polak-Jonkisz
Danuta Zwolińska
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Pediatric Nephrology / Issue 1/2013
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-012-2280-z

Other articles of this Issue 1/2013

Pediatric Nephrology 1/2013 Go to the issue

Educational Review

Cystinosis: the evolution of a treatable disease

Original Article

Spontaneous remission in children with IgA nephropathy

Abstracts

Abstracts for the AKI-PCRRT-Conference September 27 – 30, 2012, Cincinnati, Ohio, USA

Erratum

Erratum to: Ambulatory blood pressure status in children: comparing alternate limit sources

Brief Report

Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab

Erratum

Erratum to: aHUS caused by complement dysregulation: new therapies on the horizon